Abstract
Basic guidance on the photostability testing of pharmaceuticals, designed to cover manufacturing and storage over shelf life, has long been established within ICH Q1(ICH,B(10) , but the guideline does not cover the photostability of drugs during or after administration (i.e., under conditions of use). To date, there has been a paucity of guidance covering the additional testing that would be of value during the clinical preparation and use of products. This commentary suggests a systematic approach, based on realistic "worst case" photoexposure scenarios and the existing ICH Option 1 and 2 light sources, to provide valuable data to pharmaceutical manufacturers and compounding pharmacists for the safe and effective use of photosensitive injection products.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Journal of Pharmaceutical Sciences |
Vol/bind | 102 |
Udgave nummer | 11 |
Sider (fra-til) | 3888-3899 |
Antal sider | 12 |
ISSN | 0022-3549 |
DOI |
|
Status | Udgivet - nov. 2013 |